2,698
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Diabetic Retinopathy –Incidence And Risk Factors In A Community Setting- A Longitudinal Study

, , &
Pages 237-241 | Received 24 Apr 2018, Accepted 07 May 2018, Published online: 27 Jun 2018

References

  • Centers for Disease Control and Prevention, https://www.cdc.gov/visionhealth/projects/economic_studies.htm Accessed April 21, 2018.
  • Belkin M, Kalter-Leibovici O, Chetrit A, et al. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol. 2013;155:404.
  • Fong DS, Aiello L, Gardner TW, et al. American Diabetes Association. Retinopathy in Diabetes. Diabetes Care. 2004;27:S84–S87.
  • Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: XVII the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type. Ophthalmology 1998;105:1801–1815.
  • The Diabetes Control and Complications Trial Research Group: The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
  • Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18. Invest Ophthalmol Vis Sci 1998;39:233–252.
  • UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33.) Lancet 1998;352:837–853.
  • ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–244.
  • Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
  • Davidson JA, Ciulla TA, McGill JB, et al. How the diabetic eye loses vision. Endocrine 2007;32:107–116.
  • Wilkinson CP, Ferris FL, 3rd, Klein RE, et al. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677–1682.
  • Stratton IM, Kohner EM, Aldington SJ, et al. for the UKPDS Group: UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156–163.
  • Martín-Merino E, Fortuny J, Rivero-Ferrer E, et al. Incidence of retinal complications in a cohort of newly diagnosed diabetic patients. PLoS One. 2014;9:e100283.
  • Heltberg A, Andersen JS, Kragstrup J, et al. Social disparities in diabetes care: a general population study in Denmark. Scand J Prim Health Care. 2017;35:54–63.
  • Savage S, Estacio RO, Jeffers B, et al. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care. 1996;19:1243–1248.
  • Hiller R, Sperduto RD, Podgor MJ, et al. Diabetic retinopathy and cardiovascular disease in type II diabetics. The Framingham Heart Study and the Framingham Eye Study. Am J Epidemiol. 1988;128:402–409.
  • Guo VY, Cao B, Wu X, et al. Prospective Association between Diabetic Retinopathy and Cardiovascular Disease-A Systematic Review and Meta-analysis of Cohort Studies. J Stroke Cerebrovasc Dis. 2016;25:1688–1695.
  • Zhu XR, Zhang YP, Bai L, et al. Prediction of risk of diabetic retinopathy for all-cause mortality, stroke and heart failure: Evidence from epidemiological observational studies. Medicine (Baltimore). 2017;96:e5894.
  • The DCCT/EDIC Research Group Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes N Engl J Med 2017; 376:1507–1516 April 20, 2017